Ingen internetforbindelse — viser den gemte version af siden.

Amgen Inc

USUSD
← Til Screeneren

Amgen Inc (MX:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Antal børser, hvor selskabets aktier handles: 4. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om Virksomheden

Websted
amgen.com
Investorrelationer
investors.amgen.com/
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hovedkontor
Thousand Oaks, United States
Administrerende Direktør
Robert A. Bradway
Ansatte
17 900
Grundlagt
1980
Børsnoteret Siden
29.02.2008 (MX:AMGN)
Udestående Aktier
540.63 mio. pr. 2026-07-30
Free Float
539.16 mio.
Markedsværdi
226.05 mia. USD
Insidere
0.23%
Institutionelle Investorer
85.02%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
Juridisk Form
XTIQ
ISIN
US0311621009
LEI
62QBXGPJ34PQ72Z12S66
Udbetalingsgrad
60.4%
FCF
10.2 mia. USD
52%
Gæld
57.3 mia. USD
4.3 år FCF
Udbyttestreak
15 år
Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
Beskrivelse

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Børser og Tickere

BørsTickerValutaPrisType
US USA StocksAMGN primærUSD414.87 +1.82%almindelige aktier
HK Hong Kong Stock Exchange4332 sekundærHKD—
LSE London Stock Exchange0R0T IOBUSD411.854 +1.17%almindelige aktier
MX Mexican Stock ExchangeAMGN sekundærMXN7 500.0098 +0.00%almindelige aktier
XETRA XetraAMG sekundærEUR367.95 -1.39%almindelige aktier

Kurs over 3 Måneder

stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Pr. År, MX:AMGN: 180.7291 MXN (4 udb.)

Amgen Inc (AMGN) udbetaler udbytte kvartalsvis. Pr. År (12 måneder op til og med den senest annoncerede betaling): 180.7291 MXN pr. Aktie (betalinger: 4). Det svarer til cirka 2.41% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 20.11.2026. Uafbrudt udbyttehistorik: 15 år.

Ex-DatoUdbetalingBeløb%TypeTicker
2026-08-21—45.8186 MXN0.6/2.4 %kvartalsvisMX:AMGN
2026-05-15—45.8186 MXN0.6/2.4 %kvartalsvisMX:AMGN
2026-02-13—45.8186 MXN0.6/2.3 %kvartalsvisMX:AMGN
2025-11-21—43.2732 MXN0.6/2.3 %kvartalsvisMX:AMGN
2025-08-22—43.2732 MXN0.6/2.3 %kvartalsvisMX:AMGN
2025-05-16—43.2732 MXN0.6/2.2 %kvartalsvisMX:AMGN
2025-02-14—43.2732 MXN0.6/2.2 %kvartalsvisMX:AMGN
2024-11-19—40.9095 MXN0.5/2.2 %kvartalsvisMX:AMGN
2024-08-16—40.9095 MXN0.5/2.2 %kvartalsvisMX:AMGN
2024-05-16—40.9095 MXN0.5/2.1 %kvartalsvisMX:AMGN
2024-02-15—40.9095 MXN0.5/2.1 %kvartalsvisMX:AMGN
2023-11-16—38.7277 MXN0.5/2.1 %kvartalsvisMX:AMGN
2023-08-17—38.7277 MXN0.5/2.0 %kvartalsvisMX:AMGN
2023-05-17—38.7277 MXN0.5/2.0 %kvartalsvisMX:AMGN
2023-02-14—38.7277 MXN0.5/1.9 %kvartalsvisMX:AMGN
2022-11-16—35.2731 MXN0.5/1.9 %kvartalsvisMX:AMGN
2022-08-17—35.2731 MXN0.5/1.8 %kvartalsvisMX:AMGN
2022-05-16—35.2731 MXN0.5/1.4 %kvartalsvisMX:AMGN
2022-02-14—35.2731 MXN0.5/0.9 %kvartalsvisMX:AMGN
2021-11-16—32.0003 MXN0.4/0.4 %kvartalsvisMX:AMGN
annonce

Største Ejere

EjerAndelAktierRapportdato
Blackrock Inc.9.13%49.36 mio.2026-06-30
Vanguard Capital Managem…6.52%35.25 mio.2026-06-30
State Street Corporation5.65%30.56 mio.2026-06-30
Capital World Investors5.38%29.08 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%17.13 mio.2026-06-30
Invesco Ltd.3.02%16.32 mio.2026-06-30
Geode Capital Management…2.9%15.7 mio.2026-06-30
Charles Schwab Investmen…2.78%15.03 mio.2026-06-30
Vanguard Portfolio Manag…2.75%14.85 mio.2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%13.99 mio.2026-06-30
Morgan Stanley2.53%13.65 mio.2026-06-30
Invesco QQQ Trust, Serie…2.15%11.61 mio.2026-08-31
SCHWAB STRATEGIC TRUST-S…1.81%9.79 mio.2026-05-31
Income Fund of America1.44%7.76 mio.2026-06-30
iShares Trust-iShares Co…1.35%7.28 mio.2026-07-31
Wells Fargo & Company1.34%7.24 mio.2026-06-30
AMERICAN BALANCED FUND1.31%7.09 mio.2026-06-30
Fidelity Concord Street…1.29%6.98 mio.2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%6.6 mio.2026-08-31
WASHINGTON MUTUAL INVEST…1.16%6.27 mio.2026-06-30
BRADWAY ROBERT A (Chief…≈0.12%657 2992026-05-05
SANTOS ESTEBAN (Officer)≈0.02%84 2792026-05-05
GORDON MURDO (Officer)≈0.01%51 8372026-05-05
GRIFFITH PETER H. (Chief…≈0.01%50 7062026-05-05
REESE DAVID M. (Chief Te…≈0.01%42 8122026-05-05
GRAHAM JONATHAN P (Gener…≈0.01%40 2112026-05-05
BRADNER JAMES E. (Office…≈0.01%30 4622026-05-05
ECKERT ROBERT ANDREW (Di…≈0%26 2512026-05-19
JACKS TYLER (Director)≈0%18 2842026-05-19
KULLMAN ELLEN JAMISON (D…≈0%14 5362026-05-19